Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 3/20 | 0.63 |
| ▸ | CA1 | P00915 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA4 | P22748 | 1/20 | 0.63 |
| ▸ | CA6 | P23280 | 1/20 | 0.63 |
| ▸ | CA5A | P35218 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.63 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buthiazide SCHEMBL309110 | 1.00 | TDP1 (0.76) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| Buthiazide SCHEMBL7357204 | 0.89 | TDP1 (0.61) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| Ethiazide SCHEMBL30561875 | 0.86 | TDP1 (1.00) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| Ethiazide SCHEMBL122238 | 0.86 | TDP1 (1.00) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL13685945 | 0.85 | TDP1 (0.79) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL29925887 | 0.84 | TDP1 (0.82) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL11038368 | 0.84 | TDP1 (0.77) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL29132639 | 0.84 | LMNA (0.79) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL30561865 | 0.84 | LMNA (0.79) | TDP1LMNAALDH1A1CYP2C9CYP1A2 | |
| SCHEMBL13685954 | 0.83 | TDP1 (0.76) | TDP1LMNAALDH1A1CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119959418-A | Method for detecting bunhiazide in food | 安徽润安信科检测科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-118812461-A | Buthiazide hapten, artificial antigen and application thereof | 华南农业大学 | 2024-10-22 | — | — | CN | claimed |
| CN-117825540-A | Method for rapidly screening and detecting illegal drugs added to food for relieving alcoholism | 广电计量检测集团股份有限公司 | 2024-04-05 | — | — | CN | claimed |
| US-20260060966-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER AG (DE) | 2026-03-05 | — | — | US | disclosed |
| US-20260027091-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER AG (DE) | 2026-01-29 | — | — | US | disclosed |
| US-20250313559-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2025-10-09 | — | — | US | disclosed |
| US-20250302811-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER HEALTHCARE PHARMACEUTICALS INC. | 2025-10-02 | — | — | US | disclosed |
| CN-118812461-B | Buthiazide hapten, artificial antigen and application thereof | 华南农业大学 | 2025-08-08 | — | — | CN | disclosed |
| CN-118812461-B | Buthiazide hapten, artificial antigen and application thereof | 华南农业大学 | 2025-08-08 | — | — | CN | disclosed |
| CN-120289383-A | Method for synthesizing 3, 4-dihydrobenzothiadiazine medicine by rare earth catalysis | 北京化工大学 | 2025-07-11 | — | — | CN | disclosed |
| US-12296085-B2 | Method for extracorporeal treatment of preeclampsia and related disorders | ImMutriX Therapeutics, Inc. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-113574055-B | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-117825540-A | Method for rapidly screening and detecting illegal drugs added to food for relieving alcoholism | 广电计量检测集团股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-3645092-B1 | ELECTROSPRAY CATHETER | AVECTAS LTD (IE) | 2024-04-03 | — | — | EP | disclosed |
| US-11801364-B2 | Electrospray catheter | AVECTAS LIMITED (IE) | 2023-10-31 | — | — | US | disclosed |
| US-20230313196-A1 | COMPOSITIONS AND METHODS FOR TREATING PAIN AND ANXIETY DISORDERS | MANSELL JOHN (US) | 2023-10-05 | — | — | US | disclosed |
| EP-3423102-B1 | COMPOSITION FOR USE IN THE TREATMENT OF PREECLAMPSIA | IMMUTRIX THERAPEUTICS INC (US) | 2022-09-07 | — | — | EP | disclosed |
| WO-2022174113-A1 | AGENTS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF HYPOXIA AND ISCHEMIA-RELATED DISORDERS | MERAND PHARMACEUTICALS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20220220561-A1 | METHODS AND CLINICAL PROTOCOLS AND KITS PERTAINING TO MAKING AND USING THERAPEUTIC COMPOSITIONS FOR CELLULAR TREATMENT | Advanced ReGen Medical Technologies, LLC | 2022-07-14 | — | — | US | disclosed |
| WO-2022020756-A1 | COMPOSITIONS AND METHODS FOR TREATING PAIN AND ANXIETY DISORDERS | MANSELL JOHN (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313559-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | TNNI3, TNNT2, NDUFB3 | TDP1 1746/4885LMNA 240/4885ALDH1A1 630/4885 |
| US-20250302811-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | TNNI3, TNNT2, NDUFB3 | TDP1 1746/4885LMNA 240/4885ALDH1A1 630/4885 |
| US-20260060966-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | ALB, REN, TTR | TDP1 3958/4885LMNA 669/4885ALDH1A1 732/4885 |
| US-20260027091-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | ALB, REN, TTR | TDP1 4084/4885LMNA 649/4885ALDH1A1 717/4885 |
| US-12296085-B2 | Method for extracorporeal treatment of preeclampsia and related disorders | TEK, FLT4, PGF | TDP1 3275/4885LMNA 2393/4885ALDH1A1 4553/4885 |
| US-20220220561-A1 | METHODS AND CLINICAL PROTOCOLS AND KITS PERTAINING TO MAKING AND USING THERAPEUTIC COMPOSITIONS FOR CELLULAR TREATMENT | CD47, HAVCR2, BST2 | TDP1 934/4885LMNA 644/4885ALDH1A1 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.